Anti-TNFα in inflammatory bowel disease: from originators to biosimilars

The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs. The recent expiration of patents of some anti-TNFα biologics (such as infliximab and adalimumab) facilitated the development of biosimilar...

Full description

Bibliographic Details
Published in:Frontiers in Pharmacology
Main Authors: Zhen Zeng, Hao Lin, Mingshan Jiang, Jing Yuan, Xi Li, Yongbin Jia, Li Yang, Hu Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-07-01
Subjects:
biosimilars
originators
anti-TNFα
biologics
inflammatory bowel disease
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1424606/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1424606/full

Similar Items